(Q34956588)

English

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investiga

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 August 2017

WSG ADAPT - adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investiga (English)

1 reference

Europe PubMed Central

5 August 2017

1 reference

based on heuristic

inferred from title

7

object named as

Nadia Harbeck

0 references

author name string

Daniel Hofmann

1

1 reference

Europe PubMed Central

5 August 2017

Ulrike Nitz

2

1 reference

Europe PubMed Central

5 August 2017

Oleg Gluz

3

1 reference

Europe PubMed Central

5 August 2017

Ronald E Kates

4

1 reference

Europe PubMed Central

5 August 2017

Timo Schinkoethe

5

1 reference

Europe PubMed Central

5 August 2017

Peter Staib

6

1 reference

Europe PubMed Central

5 August 2017

publication date

19 August 2013

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

14

1 reference

Europe PubMed Central

5 August 2017

261

1 reference

Europe PubMed Central

5 August 2017

describes a project that uses

1 reference

Europe PubMed Central

26 June 2022

https://europepmc.org/article/PMC/PMC3765940

based on heuristic

inferred from PubMed Central ID database lookup

https://scigraph.springernature.com/pub.10.1186/1745-6215-14-261

0 references

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Using multigene tests to select treatment for early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Chemotherapy regimens in early breast cancer: major controversies and future outlook

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Decision-making tools to assist prognosis and treatment choices in early breast cancer: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Adjuvant chemotherapy in luminal breast cancers.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Quality assessment of HER2 testing by monitoring of positivity rates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Personalized treatment of early-stage breast cancer: present concepts and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

8 July 2018

Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

26 October 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

26 October 2018

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

26 October 2018

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

26 October 2018

Beyond staging, typing and grading. New challenges in breast cancer pathology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

26 October 2018

Declaration of Helsinki. Ethical principles for medical research involving human subjects.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765940

26 October 2018

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: Results of the pilot phase

1 reference

https://pubmed.ncbi.nlm.nih.gov/23958221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23958221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23958221

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1745-6215-14-261

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

1 reference

Europe PubMed Central

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34956588&oldid=1983520966"